Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy >â¯40â¯Gy after systemic treatment.
Strahlenther Onkol
; 194(7): 627-637, 2018 07.
Article
in En
| MEDLINE
| ID: mdl-29497791
ABSTRACT
PURPOSE:
The role of radiotherapy (RT) for nonmetastatic pancreatic cancer is still a matter of debate since randomized control trials have shown inconsistent results. The current retrospective single-institution study includes both resected and unresected patients with nonmetastasized pancreatic cancer. The aim is to analyze overall survival (OS) after irradiation combined with induction chemotherapy. PATIENTS ANDMETHODS:
Of the 73 patients with nonmetastatic pancreatic cancer eligible for the present analysis, 42 (58%) patients had adjuvant chemoradiotherapy (CRT), while 31 (42%) received CRT as primary treatment. In all, 65 (89%) had chemotherapy at any time before, during, or after RT, and 39 (53%) received concomitant CRT. The median total dose was 50â¯Gy (range 12-77â¯Gy), while 61 (84%) patients received >40â¯Gy.RESULTS:
With a median follow-up of 22 months (range 1.2-179.8 months), 14 (19%) are still alive and 59 (81%) of the patients have died, whereby 51 (70%) were cancer-related deaths. Median OS and the 2year survival rate were 22.9 months (1.2-179.8 months) and 44%, respectively. In addition, 61 (84%) patients treated with >40â¯Gy had a survival advantage (median OS 23.7 vs. 17.3 months, pâ¯= 0.026), as had patients with 4 months minimum of systemic treatment (median OS 27.5 vs. 14.3 months, pâ¯= 0.0004).CONCLUSION:
CRT with total doses >40â¯Gy after induction chemotherapy leads to improved OS in patients with nonmetastatic pancreatic cancer.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Radiotherapy Dosage
/
Chemoradiotherapy
/
Induction Chemotherapy
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Strahlenther Onkol
Journal subject:
NEOPLASIAS
/
RADIOTERAPIA
Year:
2018
Type:
Article
Affiliation country:
Austria